Company intelligence / Profile preview

Hemispheric

Oslo, Oslo, Norwayhemisphericinstitute.org ↗

Ownership: Private
Development stage: Other

Overview

Hemispherian is developing a new class of small molecule drugs that target the TET2 enzyme. Their lead compound, currently in late preclinical development, aims to treat glioblastoma by restoring normal epigenetic function and inducing cancer cell death. The approach shows high selectivity for cancer cells and good tolerability in normal tissues. No clinical results are available yet as programs are preclinical.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Hemispheric.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hemispheric.

Explore the full profile